GoodRx Care vs Hers: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher & Publisher
Hers beats GoodRx Care overall, scoring 7.3/10 vs 6.2/10. GoodRx Care is more affordable at $119/mo vs $199/mo. Choose GoodRx Care for users who want fda-approved brand-name glp-1 access at marke. Choose Hers for women who want brand-name wegovy (injection or pill) at $149.
A side-by-side look at GoodRx Care and Hers to help you decide. We compare them on:
- •Starting price per month
- •Our overall score, out of 10
- •Medication type, brand-name or compounded
- •Whether they accept insurance
- •Who each one is best for
GoodRx Care
#46 of 53GoodRx Care was restructured in late 2025 from a pay-per-visit model into a telemedicine subscription: $39/mo intro rate (through January 2026) → $119/mo standard. Medication is priced aggressively: Ozempic/Wegovy $199/mo intro for the first 2 fills, then $349/mo standard. Oral Wegovy pill available at $149-199/mo.
Visit GoodRx CareHers
#32 of 53The women's health arm of Hims & Hers Health (NYSE: HIMS). In 2026 Hers signed a direct Novo Nordisk partnership adding FDA-approved Wegovy (pen and pill) at $149/mo and Zepbound via the Lilly partnership, alongside their existing compounded semaglutide and new compounded tirzepatide programs.
Visit Hers| Feature | GoodRx Care | Hers |
|---|---|---|
| Why each one | The only GLP-1 prescribing service integrated with the largest prescription discount platform in the US, automatically finding the cheapest pharmacy price for your medication. | The only major women-focused telehealth platform with both a direct Novo Nordisk partnership (Wegovy pen + pill from $149/mo) and a Lilly partnership (Zepbound access) alongside compounded semaglutide and tirzepatide. |
| Our Score | 6.2/10 | 7.3/10 |
| Starting Price | $119/mo | $199/mo |
| Medication Type | Brand | Both |
| Insurance Accepted | Yes | No |
| Best For | Users who want FDA-approved brand-name GLP-1 access at market-leading subscription pricing, $199/mo Wegovy intro, $349/mo standard, plus oral Wegovy pill | Women who want brand-name Wegovy (injection or pill) at $149/mo via the 2026 Novo Nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand |
| Watch out for | Model changed from pay-per-visit to subscription, users expecting à-la-carte pricing should double-check current terms | Pending federal enforcement action against the parent company. On July 29, 2026 the FTC, joined by Utah and California acting through Los Angeles County Counsel, filed a complaint against Hims & Hers Health, Inc. in the U.S. District Court for the Northern District of California, alleging violations of the FTC Act and the Restore Online Shoppers' Confidence Act over subscription billing, cancellation friction, and sharing consumer health information with advertising platforms. Case status is Pending. These are allegations, not findings. |
| Ranking | #46 | #32 |
| Get started | Visit GoodRx Care | Visit Hers |
Pros & Cons Compared
GoodRx Care
Pros
- +2026 subscription rewrite, $119/mo standard membership with medication priced among the lowest on the market
- +Wegovy/Ozempic intro pricing ($199/mo for first 2 fills) is market-leading for brand-name access
- +Oral Wegovy pill available at $149-199/mo, one of the cheapest oral semaglutide routes
- +Insurance accepted, GoodRx's integration with savings cards can stack with coverage
Cons
- −Model changed from pay-per-visit to subscription, users expecting à-la-carte pricing should double-check current terms
- −Compounded GLP-1s are de-emphasized on current marketing, may no longer be available
- −Subscription model means ongoing monthly fee even in maintenance months
- −Follow-up clinical care is still basic compared to dedicated GLP-1 platforms
Hers
Pros
- +2026 Novo Nordisk partnership, FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
- +Zepbound access via the Lilly/Hims-Hers partnership announced 2026
- +Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
- +Broader women's health platform, integrates weight loss with hormonal, skin, and wellness services
Cons
- −Pending federal enforcement action against the parent company. On July 29, 2026 the FTC, joined by Utah and California acting through Los Angeles County Counsel, filed a complaint against Hims & Hers Health, Inc. in the U.S. District Court for the Northern District of California, alleging violations of the FTC Act and the Restore Online Shoppers' Confidence Act over subscription billing, cancellation friction, and sharing consumer health information with advertising platforms. Case status is Pending. These are allegations, not findings.
- −Membership + medication are billed separately ($39 first month / $149 ongoing membership), so total both line items before comparing prices
- −Support runs at big-platform scale, fine for routine refills, less personal if you want high-touch care
- −Compounded pricing starts at $199/mo with stepped pricing at higher doses, budget for the dose you'll end up on, not the entry dose
- −Zepbound access priced at ~$1,899/mo (brand cash) via the Lilly partnership, read as access, not value
Our Verdict
Hers edges out GoodRx Care with a score of 7.3/10 vs 6.2/10. If budget is your priority, GoodRx Care is $119/mo for the first month, rises after compared to Hers from $199/mo. GoodRx Care accepts insurance, which can significantly reduce your out-of-pocket costs. Hers offers both brand-name and compounded medications, giving you more flexibility. Choose GoodRx Care if you want: users who want fda-approved brand-name glp-1 access at market-leading subscription pricing, $199/mo wegovy intro, $349/mo standard, plus oral wegovy pill. Choose Hers if you want: women who want brand-name wegovy (injection or pill) at $149/mo via the 2026 novo nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand.
Cheapest in our index
Embody
$69/mo flat rate · 7.3/10 · Compounded
Both GoodRx Care and Hers start above the cheapest program we track. Across all 53 providers in our index, that floor is Embody at a flat $69/mo, the same rate at every dose, price checked July 31, 2026. It scores 7.3/10 and is not the highest-scored provider in our full rankings, so this is a cost floor rather than a recommendation. Worth knowing before you decide.
Read Full Reviews
Related comparisons
Other matchups readers comparing GoodRx Care or Hers tend to look at next.
- GoodRx Care vs Found$129/mo
- GoodRx Care vs Oak Longevity$119/mo
- GoodRx Care vs Ro$149/mo
- Hers vs Sprout Health$199/mo
- Hers vs Enhance MD$212/mo
- Hers vs MEDVi$179/mo
Not sure which one is right for you?
Answer a few quick questions and we'll match you to the best GLP-1 provider for your needs. Or keep exploring below.
Our pick of these two: Hers · 7.3/10